阿司匹林被拉下神坛，这 8 项年度研究不可错过(3)

[1] Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial[J]. The Lancet, 2018:S014067361831924X.

[2] The ASCEND Study Collaborative Group. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. N Engl J Med. 2018; doi:10.1056/NEJMoa1804988.

[转载出处：www.ii77.com]

[3] Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet. 2018; August 27, 2018.

[4] Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation. N Engl J Med. 2018 Aug 27.

[5] Transcatheter Mitral-Valve Repair in Patients with Heart Failure. N Engl J Med. 2018 Sep 23.

[6] Clinical Benefit of Evolocumab by Severity and Extent of CoronaryArteryDisease:AnAnalysisfromFOURIER[J].Circulation,2018:CIRCULATIONAHA.118.034309.

[7]  TWO YEAR ANALYSIS OF THE SAFETY AND TOLERABILITY OF EVOLOCUMAB: THE OSLER-1 STUDY[J]. Journal of the American College of Cardiology, 2015, 65(10):A1364.

[8] Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial. Lancet. 2018;doi:10.1016/S0140-6736(18)31719-7.

[9] Online Angiography Image-Based FFR Assessment During Coronary Catheterization: A Single-Center Study.[J]. Journal of Invasive Cardiology, 2018.

[10] Kornowski R , Vakninassa H , Assali A , et al. Online Angiography Image-Based FFR Assessment During Coronary Catheterization: A Single-Center Study.[J]. Journal of Invasive Cardiology, 2018.

[11] Baseline characteristics and treatment of patients in Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)[J]. European Journal of Heart Failure, 2014, 16(7):817-825.

[12] Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med 2018; doi:10.1056/NEJMoa1812851.